Literature DB >> 17240843

Differences in tolerance to anti-hyperalgesic effects between chronic treatment with morphine and fentanyl under a state of pain.

Satoshi Imai1, Minoru Narita, Seiko Hashimoto, Atsushi Nakamura, Kan Miyoshi, Hiroyuki Nozaki, Nana Hareyama, Tomoe Takagi, Masami Suzuki, Michiko Narita, Tsutomu Suzuki.   

Abstract

The present study was undertaken to investigate the possible change in anti-hyperalgesic effect following repeated treatment with morphine or fentanyl using the dose to improve the thermal hyperalgesia under an inflammatory pain-like state. The anti-hyperalgesic effect induced by fentanyl in complete Freund's adjuvant (CFA)-pretreated mice rapidly disappeared during the consecutive administration of fentanyl, whereas morphine preserved its potency of anti-hyperalgesic effect. In addition, repeated treatment with fentanyl, but not morphine, resulted in the increase in levels of phosphorylated-mciro-opioid receptor (MOR) associated with the enhanced inactivation of protein phosphatase 2A and the reduction in Rab4-dependent MOR resensitization. Next, we investigated the specific involvement of the opioid receptor types and MOR subtypes in analgesic properties of morphine and fentanyl in the mouse spinal cord. In the competitive displacement binding assay with [1H]DAMGO, no significant difference in the binding affinity to MOR between morphine and fentanyl was noted in membranes obtained from the mouse spinal cord. Furthermore, there was no significant difference between morphine and fentanyl in either antinociceptive effect or G-protein activation in mice partially lacking MOR-1B, which shows a greater resistance to agonist-induced desensitization than for other MOR subtypes. These findings point out the possibility that the chronic treatment with fentanyl may cause the different modulation from chronic treatment with morphine on either the internalization or resensitization of MORs in the spinal cord under a pain-like state. The present data provide the first evidence for the mechanism underlying the development of tolerance to fentanyl-induced anti-hyperalgesic effect under chronic pain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17240843

Source DB:  PubMed          Journal:  Nihon Shinkei Seishin Yakurigaku Zasshi        ISSN: 1340-2544


  6 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

2.  Possible involvement of prolonging spinal µ-opioid receptor desensitization in the development of antihyperalgesic tolerance to µ-opioids under a neuropathic pain-like state.

Authors:  Minoru Narita; Satoshi Imai; Atsushi Nakamura; Ayumi Ozeki; Megumi Asato; Mahardian Rahmadi; Yuka Sudo; Minoru Hojo; Yasuhito Uezono; Lakshmi A Devi; Naoko Kuzumaki; Tsutomu Suzuki
Journal:  Addict Biol       Date:  2011-08-04       Impact factor: 4.280

Review 3.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

4.  Possible involvement of β-endorphin in a loss of the coordinated balance of μ-opioid receptors trafficking processes by fentanyl.

Authors:  Satoshi Imai; Yuka Sudo; Atsushi Nakamura; Ayumi Ozeki; Megumi Asato; Minoru Hojo; Lakshmi A Devi; Naoko Kuzumaki; Tsutomu Suzuki; Yasuhito Uezono; Minoru Narita
Journal:  Synapse       Date:  2011-04-11       Impact factor: 2.562

5.  Chronic inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat.

Authors:  Melissa L Mehalick; Susan L Ingram; Sue A Aicher; Michael M Morgan
Journal:  J Pain       Date:  2013-10-22       Impact factor: 5.820

6.  Changes in the rewarding effects induced by tramadol and its active metabolite M1 after sciatic nerve injury in mice.

Authors:  Atsushi Nakamura; Minoru Narita; Kan Miyoshi; Keiko Shindo; Daiki Okutsu; Masami Suzuki; Kimio Higashiyama; Tsutomu Suzuki
Journal:  Psychopharmacology (Berl)       Date:  2008-08-29       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.